6-甲氧基-2H-1,4-苯并噻嗪-3(4H)-酮 | 99286-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 6-甲氧基-2H-1,4-苯并噻嗪-3(4H)-酮
• 英文名称: 6-methoxy-2H-benzo[b][1,4]thiazin-3(4H)-one
• 英文别名: 6-Methoxy-2,4-dihydro-1,4-benzothiazin-3-one；6-methoxy-4H-1,4-benzothiazin-3-one
• CAS: 99286-44-9
• 化学式: C₉H₉NO₂S
• 分子量: 195.242
• InChiKey: BHBDNZLTNMQLQX-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C(Solv: ethanol (64-17-5))
• 沸点：
  393.2±42.0 °C(Predicted)
• 密度：
  1.282±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Methoxy-2,4-dihydro-1,4-benzothiazin-3-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Methoxy-2,4-dihydro-1,4-benzothiazin-3-one
CAS number: 99286-44-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9NO2S
Molecular weight: 195.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲氧基-2H-1,4-苯并噻嗪-3(4H)-酮 在 四丁基溴化铵 劳森试剂 、 氢氧化钾 、 一水合肼 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.33h， 生成 (6-Methoxy-2H-benzo[1,4]thiazin-3-yl)-hydrazine
  参考文献：
  名称：

  Grandolini; Rossi; Tiralti, Farmaco, Edizione Scientifica, 1985, vol. 40, # 4, p. 221 - 236

  摘要：

  DOI：
• 作为产物：
  描述：

  [(4-甲氧基-2-硝基苯基)硫代]乙酸乙酯 在 铁粉 、 溶剂黄146 作用下， 反应 3.0h， 以93%的产率得到6-甲氧基-2H-1,4-苯并噻嗪-3(4H)-酮
  参考文献：
  名称：

  II型细菌拓扑异构酶的新型N-联氨基哌啶抑制剂：hERG活性降低的广谱抗菌剂

  摘要：

  新型的细菌II型拓扑异构酶的非氟喹诺酮抑制剂（DNA促旋酶和拓扑异构酶IV）对于开发不受靶标介导的氟喹诺酮类交叉耐药性影响的新型抗菌剂具有重要意义。具有通过碳与乙基桥连接的双环芳族部分的氨基哌啶，例如1，通常显示出强效的广谱抗菌活性，包括对喹诺酮类耐药的菌株，但受到强的hERG抑制作用（IC 50 = 3μM/ 1） 。我们现在公开的发现是，新的1的类似物具有连接到乙基桥的N-连接的环状酰胺部分，例如24m，保留了其的广谱抗菌活性。1，但显示出显着更少的hERG抑制作用（24 m时IC 50 = 31μM）和高于1的游离分数。一种优化的类似物化合物24l在狗的大腿感染模型中在狗中表现出中等清除率，并且有望抵抗金黄色葡萄球菌。

  DOI：

  10.1021/jm2008826

文献信息

• Heterocyclic aldose reductase inhibitors and methods of using them
  申请人：Carbipem

  公开号：US04755509A1

  公开（公告）日：1988-07-05

  The invention relates to new compounds of the formula: ##STR1## Aldose reductase inhibitors. Treatment of certain complications of diabetes.

  这项发明涉及新化合物，其公式为：##STR1## 醛糖还原酶抑制剂。治疗糖尿病的某些并发症。
• ALPHA-SYNUCLEIN LIGANDS
  申请人：Washington University

  公开号：US20170189566A1

  公开（公告）日：2017-07-06

  The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).

  本发明通常涉及作为α-突触核蛋白配体有用的各种化合物。该发明进一步涉及使用这些化合物及其放射标记类似物用于检测突触核蛋白病，包括帕金森病（PD）的方法。
• Photochemical Deracemization of Chiral Sulfoxides Catalyzed by a Hydrogen-Bonding Xanthone Sensitizer
  作者：Laura Wimberger、Thilo Kratz、Thorsten Bach

  DOI：10.1055/s-0039-1690034

  日期：2019.12

  photochemical behavior was studied in the presence of xanthone and thioxanthone sensitizers. While acyclic sulfoxides showed only decomposition, chiral benzothiazinone-1-oxides with a stereogenic sulfur atom underwent a stereomutation upon irradiation at λ = 366 nm in the presence of catalytic quantities of a xanthone sensitizer. A chiral xanthone with a 1,5,7-trimethyl-3-azabicyclo-[3.3.1]nonan-2-one

  纪念迪特·恩德斯 抽象的 制备了几种具有内酰胺氢键位的手性亚砜，并在x吨酮和噻吨酮敏化剂的存在下研究了它们的光化学行为。虽然无环亚砜仅显示分解，但具有催化性硫原子的手性苯并噻嗪酮-1-氧化物在催化量的irradiation吨酮敏化剂存在下于λ= 366 nm照射时发生了立体突变。以1,5,7-三甲基-3-氮杂双环-[3.3.1] nonan-2-one骨架的手性黄酮以催化量（5 mol％）使用，以实现外消旋苯并噻嗪酮-1-氧化物的脱硫反应。在乙腈溶液中。可以成功地对五种底物进行高效脱硫，且ee最高可达55％。 制备了几种具有内酰胺氢键位的手性亚砜，并在x吨酮和噻吨酮敏化剂的存在下研究了它们的光化学行为。虽然无环亚砜仅显示分解，但具有催化性硫原子的手性苯并噻嗪酮-1-氧化物在催化量的irradiation吨酮敏化剂存在下于λ= 366 nm照射时发生了立体突变。以1,5,7-三甲基-3-氮杂双环-[3
• Compounds for the treatment of multi-drug resistant bacterial infections
  申请人：AstraZeneca AB

  公开号：US07875715B2

  公开（公告）日：2011-01-25

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有其作为活性成分的药物组合物，以及它们作为药物的使用和用于制造用于治疗温血动物（如人类）细菌感染的药物的使用。特别地，本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物用于制造用于治疗温血动物（如人类）细菌感染的药物。
• COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS
  申请人：Breault Gloria

  公开号：US20110092495A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。特别是本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。